Brief: Spectrum Pharmaceuticals Receives Permanent J-Code For Rolvedon™ (Eflapegrastim-Xnst) Injection (J1449) From U.S. Centers For Medicare & Medicaid Services
08/02/2023 12:12
Feb 8 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS RECEIVES PERMANENT J-CODE FOR
ROLVEDON™
(EFLAPEGRASTIM-XNST) INJECTION (J1449) FROM U.S. CENTERS FOR
MEDICARE & MEDICAID SERVICES
* SPECTRUM PHARMACEUTICALS INC - PERMANENT J-CODE, J1449,
ISSUED
FOR ROLVEDON INJECTION EFFECTIVE AS OF APRIL 1, 2023
Source text for Eikon: ID:nBw2lz5tva
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary